

Michael Patrick Sheehan, MD, FAAD

1725 Washington Street
Columbus, IN 47201
(812)360-5366
mpsheeha@iu.edu

Education

Board Certified American Academy of Dermatology 2011-Current

Dermatology Residency

Indianapolis, IN
Indiana University School of Medicine 2008-2011
Top Resident Award

Internal Medicine Residency, Categorical Year

Indianapolis, IN
Indiana University School of Medicine 2007-2008

Medical School

Indianapolis, IN
Indiana University School of Medicine 2003-2007
Elected to Alpha Omega Alpha Honor Society

Johns Hopkins University School of Medicine

Baltimore, MD
Summer Institute in Anatomy 2001
Graduated with Top of Class Honors

Undergraduate Training

Terre Haute, IN
Indiana State University 1998 - 2003
Bachelor of Science
Graduated with highest distinction

Michael Patrick Sheehan, MD, FAAD

Clinical Study Experience

Sponsor: Alumis, Inc.

Phase: 2

Role: Principal Investigator

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis

December 2022 – September 2023

Sponsor: Sanofi

Phase: 3

Role: Principal Investigator

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults

April 2025 – Present

Sponsor: Moonlake Immunotherapeutics AG

Phase: 3

Role: Principal Investigator

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa

June 2025 – Present

Sponsor: Moonlake Immunotherapeutics AG

Phase: 3

Role: Principal Investigator

An open-label, single-arm study to evaluate the pharmacokinetics and safety of subcutaneous sonelokimab in adolescents aged ≥ 12 to ≤ 17 years at the time of study inclusion with active moderate to severe hidradenitis suppurativa

December 2024 – Present

Sponsor: Alumis, Inc.

Phase: 3

Role: Principal Investigator

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis

July 2024 – February 2026

Sponsor: Moonlake Immunotherapeutics AG

Phase: 3

Role: Principal Investigator

A parallel-group treatment, phase 3, randomized, double-blind, 2 arm study to investigate the efficacy and safety of subcutaneous sonelokimab compared with placebo in male and female participants aged 18 years or over with active moderate to severe hidradenitis suppurativa

May 2024 - Present

Sponsor: Alumis, Inc.

Phase: 3

Role: Principal Investigator

Michael Patrick Sheehan, MD, FAAD

An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001 (ONWARD3)

December 2024 – Present

Sponsor: Lilly

Phase: 4

Role: Principal Investigator

A Study to Investigate the Efficacy of Lebrikizumab in Participants with Atopic Dermatitis with Limited Body Surface Area Involvement and High Itch Burden

June 2025 – Present

Sponsor: University of Pennsylvania

Phase: 4

Role: Principal Investigator

Prevention of cardiovascular disease and mortality in patients with psoriasis or psoriatic arthritis: Translating guidelines of care to better outcomes for patients with psoriatic disease

November 2023 - Present

Sponsor: Sanofi

Phase: 2

Role: Sub-Investigator

A parallel-group treatment, Phase 2, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR444656 in adult participants with moderate to severe hidradenitis suppurativa

October 2023 – February 2026

Sponsor: Target PharmaSolutions

Role: Sub-Investigator

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

February 2020 - Present

Sponsor: CorEvitas

Role: Sub-Investigator

Corrona Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness

October 2021 - Present

Sponsor: Bristol-Meyers Squibb Company

Phase: 2

Role: Sub-Investigator

A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis

May 2022 – September 2022

Sponsor: Taro Pharmaceuticals, Inc.

Phase: 4

Role: Sub-Investigator

Michael Patrick Sheehan, MD, FAAD

A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Ruxolitinib topical cream 1.5% (Taro Pharmaceuticals U.S.A., Inc.) to Opzelura (Ruxolitinib) cream and both active treatments to a placebo control in the treatment of mild-to-moderate atopic dermatitis

October 2023 – December 2024

Sponsor: University of Pennsylvania

Phase: 4

Role: Sub-Investigator

A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis / Light Treatment Effectiveness (LITE) Study

January 2020 – July 2024

Sponsor: Regeneron Pharmaceuticals, Inc.

Phase: 3

Role: Sub-Investigator

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand and Foot Dermatitis

April 2021 – February 2023

Sponsor: Celgene International II Sàrl

Phase: 2

Role: Sub-Investigator

A Phase 2, Multicenter, Global, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Severe Atopic Dermatitis

June 2021 – December 2022

Sponsor: Dermtech Operation, Inc.

Role: Sub-Investigator

A Sample Collection Study to Assess the Prevalence of Gene Mutations Associated with Photoaging in Facial Skin from Adults: Establishing Population Norms

May 2022 – January 2024

Sponsor: Moonlake Immunotherapeutics AG

Phase: 2

Role: Sub-Investigator

Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sonelokimab in Patients with Active Moderate to Severe Hidradenitis Suppurativa

May 2022 – October 2023

Sponsor: Alumis Inc.

Phase: 2

Role: Sub-Investigator

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ESK-001 in Patients with Plaque Psoriasis

June 2023 – February 2025

Michael Patrick Sheehan, MD, FAAD

Sponsor: Ventyx Biosciences, Inc.

Phase: 2

Role: Sub-Investigator

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in participants with Moderate to Severe Psoriasis

November 2022 – February 2024

Sponsor: Gilead Sciences, Inc.

Phase: 2a

Role: Sub-Investigator

A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)

February 2023 – August 2024

Sponsor: DICE Therapeutics, Inc.

Phase: 2

Role: Sub-Investigator

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis

June 2023 – March 2024

Memberships and Affiliations

Indiana Academy of Dermatology, President	2026-Current
Indiana Academy of Dermatology, Vice President	2024-2026
Indiana University Department of Dermatology - Adjunct Clinical Assistant Professor	2011-Current
Richard L. Roudebush VA Medical Center Clinical Faculty	2011-Current
ACDS Editorial Publications Committee Chair	2020-Current
<i>Dermatitis</i> Journal Editorial Board Member	2011-Current
Columbus Regional Hospital Staff	2011-Current
Indiana State Medical Association Member	2011-Current
American Academy of Dermatology Fellow	2011-Current
American Contact Dermatitis Society (ACDS) Member	2009-Current
Marian University College of Osteopathic Medicine Clinical Professor	2013-2019
ACDS Vice President	2017-2019
ACDS Executive Board	2014-2019
ACDS Annual Meeting Chair	2015
President Bartholomew/Brown County Medical Society	2014-2015
ACDS Quality Assurance Committee	2013-2015

Awards and Recognition

Michael Patrick Sheehan, MD, FAAD

ACDS Mid-Career Award Recipient	2020
Top Doctors Award Castle Connolly	2018-2024
Volunteer Faculty Resident Teacher of the Year Award Awarded by Indiana University School of Medicine, Department of Dermatology for excellence in resident education.	2013
Cleveland J. Francoeur Outstanding Dermatology Resident Award Awarded by Indiana University School of Medicine, Department of Dermatology to the top graduating dermatology resident.	2011
Chief Resident, IU Department of Dermatology	2011
Winner of American Contact Dermatitis Society Contact Allergen Bee A contest for dermatology residents to identify and reward residents who are most knowledgeable regarding contact dermatitis. Sponsored by <i>Dermatitis</i> , The journal for the American Contact Dermatitis Society	2010
Recognition for Excellence in Consult Services Awarded by Clarian Hospitalist Group for excellence in service.	2009
Graduate of the Last Decade (G.O.L.D.) Award Awarded by Indiana State University to provide recognition for the outstanding achievements of graduates of the past ten years of Indiana State University	2009
Department of Dermatology Award Awarded by Indiana University School of Medicine, Department of Dermatology to the top senior medical student demonstrating an outstanding performance in dermatology	2007

Publications and Presentations

American Academy of Dermatology 2024 Annual Meeting. San Diego, CA. Contact Dermatitis Session Guest Speaker – Occupational Contact Dermatitis.

Skinternal Medicine Course 2023. Guest Speaker – JAK Inhibitors: You Do Know JAK.

Aukerman E, Battiston G, Sheehan M, Robinson S. Chemical Analysis of Common North American Hardwoods: Developing a 'Safe' List for Household Use. (In submission)

American Academy of Dermatology 2023 Annual Meeting. New Orleans, LA. Contact Dermatitis Session Guest Speaker – Occupational Contact Dermatitis.

Michael Patrick Sheehan, MD, FAAD

Skinternal Medicine Course 2022. Guest Speaker - Rash Decisions: Eczema in Kids and Adults.

Skinternal Medicine Course 2022. Guest Speaker - Eczema Treatment: What's New, What's Old, and How to Use these Medications.

Skinternal Medicine Course 2021. Guest Speaker - Lower Leg Conundrums.

Sheehan M. Plant Associated Irritant & Allergic Contact Dermatitis (Phytocontact dermatitis). *Dermatologic Clinics*. 38:389-398, July 2020.

American Academy of Dermatology 2019 Annual Meeting. Washington, DC. Director of Contact Dermatitis Session & Guest Speaker - What to Do When Patch Testing is Negative?

American Academy of Dermatology 2019 Annual Meeting. Washington, DC. Speaker at Basics of Patch Testing Symposium – The Mechanics of Performing Patch Testing.

American Contact Dermatitis Society 2019 Annual Meeting. Washington, DC. Guest Speaker - What to Do When Patch Testing is Negative?

Sheehan M, Zirwas M. Textiles & Shoes. Fisher's Contact Dermatitis 7th Edition.

Turrentine JE, Sheehan MP, Cruz PD. Allergic Contact Dermatitis. Fitzpatrick's Dermatology 9th Edition

Skinternal Medicine Course. April 2018. Jeffersonville, IN. Common Conundrums of the Lower Extremities. Speaker.

Uyesugi B, Sheehan M. Patch Testing Pearls. Clinical Reviews in Allergy and Immunology (Accepted for publication).

American Academy of Dermatology 2018 Annual Meeting. San Diego, California. Director of What to do When Patch Testing is Negative Symposium.

American Academy of Dermatology 2018 Annual Meeting, San Diego, California. Basics of Patch Testing from the American Contact Dermatitis Society. Speaker.

Brinkworth, MD, Aouthmany M, Sheehan M. Histamine 2 Receptor Antagonists and Proton Pump Inhibitors. *Dermatitis*. 27(3):100-109, May/June 2016.

Schalock PC, Crawford G, Nedorost S, Scheinman PL, Atwater AR, Mowad C, Brod B, Ehrlich A, Watsky KL, Sasseville D, Silvestri D, Worobec SM, Elliott JF, Honari G, Powell DL, Taylor J, DeKoven J, Lampel H, Dunnick C, Jacob SE, Sheehan M, Botto N. Patch Testing for Evaluation of Hypersensitivity to Implanted Metal Devices: A Perspective From the American Contact Dermatitis Society. *Dermatitis*. 27(5):241-247,

Michael Patrick Sheehan, MD, FAAD

September/October 2016.

LIAAS Derm Allergy Day 2016. Mineola NY. Pearls & Pitfalls of Patch Testing. Speaker.

Hill H, Goldenberg A, Sheehan M, Patel A, and Jacob S, Nickel-Free Alternatives Raise Awareness. *Dermatitis* 26(6):245-253, November/December 2015.

Sheehan M. Avocational contact dermatitis - pearls for lifestyle alternatives. *Current Treatment Options in Allergy*. 2015 Oct; 1-11.

American Academy of Dermatology 2015 Annual Meeting. San Francisco, California. Director of Contact Dermatitis MOC Session.

Sheehan M. Therapeutics in allergic contact dermatitis, when avoidance fails. *Current Treatment Options in Allergy*. 2014 Dec; 1(4):337-347.

Sheehan M, Fowler J, Corona R. Chronic hand eczema. *UpToDate*. July 2014.

American Contact Dermatitis Society 2014 Annual Meeting, Denver, Colorado. Director of Contact Dermatitis Breakout Symposium.

American Academy of Dermatology 2014 Annual Meeting. Denver, Colorado. Director of Contact Dermatitis MOC Session.

Indiana Academy of Dermatology 2013 Fall Meeting, Indianapolis, IN. Speaker.

American Academy of Dermatology 2013 Annual Meeting. Miami, FL. Director of Contact Dermatitis MOC Session.

American Academy of Dermatology 2013 Annual Meeting. Miami, FL. Contact Dermatitis Forum Speaker.

American Academy of Dermatology 2012 Annual Meeting. San Diego, CA. Contact Dermatitis Forum Speaker.

Staser K, Ezra N, Sheehan M, Mousdicas N. The Beak Sign: a clinical clue to airborne contact dermatitis. *Dermatitis*. 2014 March/April; 25(2):97-98.

Huynh M, Sheehan M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Extremities. *The Dermatologist*. 2013 Jun;21(6):1-2.

Sheehan M, Huynh M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Mouth, Lips, and Perioral Region. *The Dermatologist*. 2013 May;21(5):1-3.

Michael Patrick Sheehan, MD, FAAD

Huynh M, Sheehan M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Anogenital. The Dermatologist. 2013 April;21(4):1-3.

Huynh M, Sheehan M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Feet. The Dermatologist. 2013 Feb;21(2):1-2.

Sheehan M, Huynh M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Hands. The Dermatologist. 2013 Jan;21(1):1-3.

Huynh M, Sheehan M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Neck. The Dermatologist. 2012 Nov;20(11):1-2.

Huynh M, Sheehan M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Eyelids. The Dermatologist. 2012 Oct;20(10):1-2.

Sheehan M, Zemtsov A. Long-lasting allergic patch test reaction to methyl methacrylate. Dermatitis. 2012 Sept/Oct; 23(5):242-243.

Huynh M, Sheehan M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Face. The Dermatologist. 2012 Aug;20(8):1-2.

Huynh M, Sheehan M, Chung M, Zirwas M, and Feldman S, Regional Atlas of Contact Dermatitis: Scalp. The Dermatologist. 2012 June;20(6):44-46.

Sheehan M, Allergic Contact Dermatitis of the Foot. The Dermatologist. 2012 Nov;20(11):20-24.

Drugs in Dermatology: The A, B, C, and Ds of Group A-D Corticosteroids.
By Scott Tomerlin, PharmD and Michael Sheehan, MD. JDPA Vol 5 Num 1 Winter 2011

Comprehensive Dermatologic Drug Therapy 3rd edn. Chapter: Irritants and Allergens: When to Suspect Topical Therapeutic Agents. Sheehan, M; Zirwas, M; Mousdicas, N

Eccrine Syringomatous Carcinoma. Michael P. Sheehan. Presentation, American Academy of Dermatology Meeting 2011

Are Mattress Protectors The New Spandex? Michael P. Sheehan, Nico Mousdicas. Presentation American Contact Dermatitis Society Annual Meeting 2010

Travers J, Kozman A, Mousdicas N, Al-Hassani M, Yi Q, Hyatt A, Landis M, Sheehan M, Sparz H, Yao W, Safa C, Bina P, Haggstrom A, Kaplan M. Characterization of infected atopic dermatitis lesions reveals the presence of pharmacologic amounts of lipoteichoic acid. J Allergy Clin Immunol. 2010 January; 125(1):146

Michael Patrick Sheehan, MD, FAAD

Mercy A. Oduyungbo; Michael P. Sheehan; Anita N. Haggstrom *HLA-B*1502* Allele Associated With Carbamazepine-Induced Epidermal Necrolysis. Arch Dermatol, Dec 2010; 146: 1437 - 1438

Sheehan MS, Tackett B. IU Department of Dermatology Survival Guide, 1st Edition. 2009

Brogan TM, Tackett B, Yang MF, Sheehan MS. Interesting cases from Indiana University Medical Center. J Am Acad Dermatol. 2009; Mar; S60(3): 49

Sheehan M, Huddleston H, Mousdicas N. Picture of the month. Chronic bullous dermatosis of childhood. Archives of Pediatrics & Adolescent Medicine. 162(6):581-2, 2008 Jun.

Sandoval JA, Sheehan MP, Stonerock CE, Shafique S, Rescorla FJ, and Dalsing MC. Treatment patterns for deep venous thrombosis in hospitalized children: Are standardized protocols needed? American Venous Forum 2006

Sheehan M, Roumpf SO, Summerlin D, Billings S. Spindle cell hemangioma: report of a case presenting in the oral cavity. J Cutaneous Pathology, Accepted for publication October 2006